Sisram Medical, the Israeli manufacturer and distributor of Daxxify (daxibotulinumtoxinA), has restructured its China distribution agreement with a connected Fosun unit. The move suggests prior arrangements did not meet commercial or operational targets and signals the complexity of scaling a premium toxin product in a market dominated by lower-cost domestic competitors and regulatory uncertainty.
Daxxify's 6-month duration is a clinical differentiator in the U.S. medspa market, where practices command premium pricing for extended intervals between treatments. In China, however, price sensitivity and the prevalence of unregulated or counterfeit toxin products create headwinds. The restructuring may involve revised economics, territory adjustments, or manufacturing/supply-chain modifications.